mecfa | mecfa 26/27

MECFA Blog

Scientists work to dissolve the NETs that worsen TBI damage

Immune cells that are first responders to a traumatic brain injury appear to also contribute to the secondary damage that can occur even...

Cystic Fibrosis Medications: What You Need to Know

Cystic fibrosis is a life-threatening, genetic disease that affects patients’ ability to breathe and is marked by persistent lung...

Toothpaste ingredient may bust up cystic fibrosis biofilms

A common antibacterial substance in toothpaste may combat life-threatening diseases such as cystic fibrosis when combined with an with an...

Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on t

Program to Pursue Broad Label for PTI-428 as an Add-On Therapy to CFTR Modulator Based Treatment BRIGHTON, Mass., May 8, 2018...

Data from Spyryx Biosciences' HOPE-1 Phase 2 Clinical Trial to be Presented in a Late-Breaking O

DURHAM, N.C., May 8, 2018 /PRNewswire/ -- Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel...

Don't Forget To Register to MECFC2018

MECFC 2018 is taking place in Izmir, Turkey in March. https://lnkd.in/g79mWaP Register today! MECFC 2018 İzmir Türkiye'de yapılıyor....

Introduction of New Therapies Affects Pregnancy Rates in Women With CF, Study Reports

The overall rate at which women with cystic fibrosis are becoming pregnant dropped slightly in recent years — coinciding with the...

2nd Middle East Cystic Fibrosis Conference

Time is running out to take advantage of early registration discounts for the upcoming MECFC 2018 taking place in Izmir, Turkey in March....

Advances in the Prevention and Treatment of MRSA in Patients with Cystic Fibrosis

Active research and special expertise at Cleveland Clinic’s Adult CF Center Methicillin-resistant Staphylococcus aureus (MRSA) increases...

Sclerosis medicine can fight multi-resistant bacteria

A surprising discovery shows that a widely used and 20-year-old medicine used to treat multiple sclerosis can also beat a type of...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p